Holen Sie sich die Stockscreener-App
0.3801
8.50%
-0.0353
Handel nachbörslich:
.36
-0.0201
-5.29%
Schlusskurs vom Vortag:
$0.4154
Offen:
$0.4006
24-Stunden-Volumen:
73.45M
Relative Volume:
6.83
Marktkapitalisierung:
$87.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-179.82M
KGV:
-0.2858
EPS:
-1.33
Netto-Cashflow:
$-159.16M
1W Leistung:
-82.48%
1M Leistung:
-85.92%
6M Leistung:
-83.89%
1J Leistung:
-69.83%
1-Tages-Spanne:
$0.3312
$0.4006
1-Wochen-Bereich:
$0.3312
$2.2263
52-Wochen-Spanne:
$0.3312
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3801 | 96.15M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Finviz
Quarterly Trades: Should I set a stop loss on Gossamer Bio IncJuly 2025 Trends & Technical Pattern Based Signals - baoquankhu1.vn
Barclays downgrades Gossamer Bio (GOSS) - MSN
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Re - GuruFocus
Gossamer Bio stock downgraded by Wedbush on trial results - Investing.com South Africa
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
These Analysts Slash Their Forecasts On Gossamer Bio - Benzinga
GOSS: Analyst Downgrades and Price Target Slashes by Leerink Par - GuruFocus
GOSS Sees Significant Downgrade as Barclays Lowers Price Target - GuruFocus
This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Barclays cuts Gossamer Bio stock rating on trial results By Investing.com - Investing.com Australia
Leerink Downgrades Gossamer Bio to Market Perform From Outperform, Adjusts Price Target to $1 From $6 - marketscreener.com
Leerink cuts Gossamer Bio stock rating on trial miss - Investing.com Australia
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock²
Barclays cuts Gossamer Bio stock rating on trial results - Investing.com
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial By Investing.com - Investing.com India
Leerink cuts Gossamer Bio stock rating on trial miss By Investing.com - Investing.com Canada
GOSS: Gossamer Bio's Phase 3 Study of Seralutinib Shows Promise in PAH - GuruFocus
Gossamer Bio stock plummeted 82% today — what’s behind the crash? - MSN
Gossamer Bio’s seralutinib misses primary endpoint in PAH trial - Investing.com Australia
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - Yahoo Finance
BREAKING: Gossamer Bio Investors Should Contact Block & - GlobeNewswire
Gossamer slides on phase III readout of seralutinib in PAH - BioWorld MedTech
Gossamer Bio (GOSS) Faces Setback in Phase 3 Trial Results - GuruFocus
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Asianet Newsable
Gossamer Bio Shareholders Are Encouraged to Contact Johnson - GlobeNewswire
GOSS Faces Setback with Phase 3 PROSERA Results in Pulmonary Hyp - GuruFocus
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results - TipRanks
Gossamer Bio Reports Phase 3 Trial of Seralutinib Missed Primary Endpoint - marketscreener.com
Gossamer Bio stock tumbles 80% on trial miss By Investing.com - Investing.com Canada
Gossamer Bio Inc. (Ticker: GOSS) recently disclosed the topline data from its Phase III clinical trial, the Prosera study. - Bitget
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters
Gossamer Bio's experimental lung condition drug fails in late-stage trial - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - The Joplin Globe
Monaco Asset Management SAM Sells 2,170,584 Shares of Gossamer Bio, Inc. $GOSS - MarketBeat
How Gossamer Bio Inc. stock reacts to Fed rate cuts2025 Trading Recap & Weekly Stock Breakout Alerts - mfd.ru
Street Watch: What is FATEs P E ratio telling usJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest - AOL.com
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS) - MarketBeat
A Big Test For SeralutinibWill Gossamer's PAH Data Win Investors' Hearts This Month? - RTTNews
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance
Gossamer Bio’s Stock Whipsaws As Biotech Investors Weigh Risk, Cash Runway And Pipeline Hopes - AD HOC NEWS
Brokers Offer Predictions for Gossamer Bio FY2030 Earnings - MarketBeat
Big Money Bets On Gossamer Bio (GOSS) As Institutional Ownership Hits 81 Percent - AOL.com
Is Gossamer Bio Inc. forming a breakout patternJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - mfd.ru
MB Generational Wealth LLC Buys Shares of 1,414,824 Gossamer Bio, Inc. $GOSS - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Gossamer Bio (NASDAQ:GOSS) Trading Down 4.7%Here's What Happened - MarketBeat
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
1.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):